Videos

Aaron Waxman, MD, PhD, discusses sotatercept’s new indication and recommendation in patients newly diagnosed with PAH at intermediate to high risk.

Iltefat H. Hamzavi, MD, explains why vitiligo responds slowly, why stabilization matters, and what Tranquillo data mean for future treatment.

Linda Stein Gold, MD, and Andrew Blauvelt, MD, MBA, discuss 2-year ICONIC-TOTAL data supporting icotrokinra's benefit for scalp, genital, and hand/foot PsO.

Chris Bunick, MD, PhD, discusses 52-week UnlIMMited data showing risankizumab sustained clearance, itch relief, and quality-of-life gains.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

Iltefat H. Hamzavi, MD, discusses phase 3 Tranquillo data showing higher facial and total body repigmentation with ritlecitinib in vitiligo.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

Stay up-to-date with the latest in FDA decisions, trial readouts, and key clinician insights from all corners of endocrinology.

Chambers discusses final results from a 7-year dupilumab pregnancy registry showing no evidence of increased risk for major birth defects or other outcomes.

Leon Kircik, MD, discusses unmet needs in atopic dermatitis, the rapid pace of new therapies, and emerging agents he is watching at EADV 2026.

Leon Kircik, MD, discusses phase 1b data for ENV-294, a first-in-class oral Rac2 modulator showing EASI reductions in atopic dermatitis.

Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.

Sean Wharton, MD, PharmD, discusses the SYNCHRONIZE-2 data presented at EASD 2026, highlighting the GLP-1/glucagon dual agonist’s potential.

Joseph Rossano, MD, MS, discusses the SCOUT-HCM trial, mavacamten’s expanded indication, and what it means for pediatric oHCM.

An ARCADIA investigator says patients in practice match the 3-year trial results and outlines next steps for IL-31 research.

Up to 91% of patients reached EASI-75 at week 152 in the ARCADIA LTE, with consistent safety and gains in itch and quality of life.

At EADV 2026, Julia Mhlaba Riley, MD, discussed how hidradenitis suppurativa presents in skin of color and ways to close diagnostic and treatment gaps.

Kristina Derrick, MD, explains how prior authorization and cost limit steroid-sparing care, and how dermatologists can document corticosteroid exposure.

Final ORIGIN 3 analysis shows a 76% lower risk of kidney disease progression vs placebo through 2 years.

Ochsner Health uses multidisciplinary clinics, living donor programs, and transplant innovations to address access challenges.

Murad Alam, MD, and Elizabeth Kiracofe, MD, discuss how reimbursement, coverage, and advocacy shape dermatology access for patients with skin of color.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss dosing guidelines for the recently approved efsitora alfa-gobe.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA's approval of a new basal insulin for T2D.

An Ochsner transplant surgeon discusses 10,000 transplants and how new tools are expanding who can receive an organ.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss UACR screening for patients with CKD and T1D.

Andrea Murina, MD, weighs whether she would recommend medicine to her own children amid AI, physician burnout, and evolving residency training standards.